Pretreatment resistin levels are associated with erosive disease in early rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs and infliximab

References

• Tripathi D, Kant S, Pandey S, Ehtesham NZ. Resistin in metabolism, inflammation, and disease. FEBS J 2020;287:3141–9.
   PubMed Web of Science ®Google Scholar
• Carrión M, Frommer KW, Pérez-García S, Müller-Ladner U, Gomariz RP, Neumann E. The adipokine network in rheumatic joint diseases. Int J Mol Sci 2019;20:4091.
   PubMed Web of Science ®Google Scholar
• Lee S, Lee HC, Kwon YW, Lee SE, Cho Y, Kim J, et al. Adenylyl cyclase-associated protein 1 is a receptor for human resistin and mediates inflammatory actions of human monocytes. Cell Metab 2014;19:484–97.
   PubMed Web of Science ®Google Scholar
• Huang Q, Tao SS, Zhang YJ, Zhang C, Li LJ, Zhao W, et al. Serum resistin levels in patients with rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis. Clin Rheumatol 2015;34:1713–20.
   PubMed Web of Science ®Google Scholar
• Kontunen P, Vuolteenaho K, Nieminen R, Lehtimäki L, Kautiainen H, Kesäniemi Y, et al. Resistin is linked to inflammation, and leptin to metabolic syndrome, in women with inflammatory arthritis. Scand J Rheumatol 2011;40:256–62.
   PubMed Web of Science ®Google Scholar
• Leirisalo-Repo M, Kautiainen H, Laasonen L, Korpela M, Kauppi MJ, Kaipiainen-Seppänen O, et al. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study). Ann Rheum Dis 2013;72:851–7.
   PubMed Web of Science ®Google Scholar
• Rantalaiho V, Kautiainen H, Korpela M, Hannonen P, Kaipiainen-Seppänen O, Möttönen T, et al. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial. Ann Rheum Dis 2014;73:1954–61.
   PubMed Web of Science ®Google Scholar
• Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
   PubMed Web of Science ®Google Scholar
• van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27:261–3.
   PubMed Web of Science ®Google Scholar
• Rantalaiho V, Kautiainen H, Järvenpää S, Korpela M, Malmi T, Hannonen P, et al. Failure in longterm treatment is rare in actively treated patients with rheumatoid arthritis, but may be predicted by high health assessment score at baseline and by residual disease activity at 3 and 6 months: the 5-year followup results of the randomized clinical NEO-RACo trial. J Rheumatol 2014;41:2379–85.
   PubMed Web of Science ®Google Scholar
• Liu X. Classification accuracy and cut point selection. Stat Med 2012;31:2676–86.
   PubMed Web of Science ®Google Scholar
• Klein-Wieringa IR, van der Linden MP, Knevel R, Kwekkeboom JC, van Beelen E, Huizinga TW, et al. Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis. Arthritis Rheum 2011;63:2567–74.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Unzueta MT, Gonzalez-Juanatey C, Miranda-Filloy JA, Vazquez-Rodriguez TR, de Matias JM, et al. Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008;26:311–6.
   PubMed Web of Science ®Google Scholar
• Klaasen R, Herenius MM, Wijbrandts CA, de Jager W, van Tuyl LH, Nurmohamed MT, et al. Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis. Ann Rheum Dis 2012;71:1510–16.
   PubMed Web of Science ®Google Scholar
• Rho YH, Solus J, Sokka T, Oeser A, Chung CP, Gebretsadik T, et al. Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum 2009;60:1906–14.
   PubMed Web of Science ®Google Scholar
• Giles JT, van der Heijde DM, Bathon JM. Association of circulating adiponectin levels with progression of radiographic joint destruction in rheumatoid arthritis. Ann Rheum Dis 2011;70:1562–8.
   PubMed Web of Science ®Google Scholar
• Bruynesteyn K, van der Heijde D, Boers M, Lassere M, Boonen A, Edmonds J, et al. Minimal clinically important difference in radiological progression of joint damage over 1 year in rheumatoid arthritis: preliminary results of a validation study with clinical experts. J Rheumatol 2001;28:904–10.
   PubMed Web of Science ®Google Scholar
• Saevarsdottir S, Rezaei H, Geborek P, Petersson I, Ernestam S, Albertsson K, et al. Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial. Ann Rheum Dis 2015;74:1509–14.
   PubMed Web of Science ®Google Scholar
• Rydell E, Forslind K, Nilsson JÅ, Jacobsson LTH, Turesson C. Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis. Arthritis Res Ther 2018;20:82.
   PubMed Web of Science ®Google Scholar
• Brown RA, Spina D, Butt S, Summers GD. Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis. Clin Rheumatol 2012;313:455–61.
   Web of Science ®Google Scholar
• Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006;65:453–8.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Brahe CH, Østergaard M, Lund Hetland M, Hambardzumyan K, Saevarsdottir S, et al. Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies. Curr Med Res Opinion 2019;35:1483–93.
   PubMed Web of Science ®Google Scholar